Moxidectin (Cydectin, Quest)

Moxidectin is a second-generation macrocyclic lactone antiparasitic compound belonging to the milbemycin subclass, distinguished from avermectins like ivermectin and doramectin by its chemical structure and pharmacokinetic profile. Derived from fermentation products of Streptomyces cyaneogriseus, moxidectin was developed to provide broader spectrum activity, extended duration of effect, and potential advantages against parasites demonstrating resistance to earlier macrocyclic lactones. The compound's enhanced lipophilicity results in extensive tissue distribution and slow elimination, providing persistent antiparasitic activity that can extend protection against reinfection for weeks to months following a single treatment. This extended duration of activity has made moxidectin particularly valuable in strategic parasite control programs designed to reduce treatment frequency and simplify management logistics.

The mechanism of action of moxidectin parallels that of other macrocyclic lactones, involving high-affinity binding to glutamate-gated chloride ion channels found specifically in invertebrate nerve and muscle cells. This binding causes increased chloride ion conductance, membrane hyperpolarization, paralysis, and death of susceptible parasites. The selectivity for invertebrate-specific receptors absent in mammals provides an excellent safety margin in treated animals. Moxidectin may also interact with gamma-aminobutyric acid (GABA) receptors, contributing to its antiparasitic effects particularly against arthropod ectoparasites. Subtle differences in receptor binding characteristics between moxidectin and avermectins may contribute to the observed activity of moxidectin against some ivermectin-resistant parasite strains.

Moxidectin is commercially available in formulations designed for multiple livestock species and routes of administration. For cattle, injectable (1% or 10 mg/mL) and pour-on (0.5% or 5 mg/mL) formulations marketed under the Cydectin brand provide comprehensive endectocide activity. For horses, oral gel formulations (Quest, Quest Plus) are widely used for strategic deworming. Sheep formulations are available in some markets, addressing the significant small ruminant parasite challenges globally. The formulation options accommodate diverse management systems and producer preferences while delivering the extended duration of activity that characterizes moxidectin's pharmacokinetic profile.

Regulatory approval encompasses cattle, sheep, and horses in the United States, with specific labeled indications and withdrawal requirements for each species. Moxidectin is classified as a non-prescription product for most livestock formulations, allowing over-the-counter access while requiring producer attention to appropriate use. The compound has been positioned as an important tool in resistance management strategies, often recommended when reduced efficacy of ivermectin or other avermectins is suspected based on fecal egg count reduction testing. However, moxidectin itself is not immune to resistance development, and its use must be integrated into comprehensive parasite management programs that preserve drug efficacy for future generations of livestock producers.

Moxidectin injectable and pour-on formulations for cattle are FDA-approved for treatment and control of an extensive range of internal parasites with both immediate and persistent activity claims. Labeled gastrointestinal nematode indications include Ostertagia ostertagi (including inhibited fourth-stage larvae), Haemonchus placei, Trichostrongylus axei, T. colubriformis, Cooperia oncophora, C. punctata, C. pectinata, Bunostomum phlebotomum, Oesophagostomum radiatum, Nematodirus helvetianus, and Strongyloides papillosus. The persistent activity claims—extending protection against reinfection for 14 to 35 days depending on the parasite species—distinguish moxidectin from earlier macrocyclic lactones and support extended treatment intervals in grazing management programs.

Respiratory and tissue parasites within the moxidectin spectrum include lungworms (Dictyocaulus viviparus) causing parasitic bronchitis, with persistent activity claims providing extended protection against reinfection following treatment. Cattle grubs (Hypoderma bovis and H. lineatum) are effectively controlled when treatment is appropriately timed relative to the grub migration cycle. The extended persistent activity of moxidectin can provide protection against new grub establishment for an extended period following treatment, potentially reducing the need for multiple treatments during the fly season when the product is administered before significant larval accumulation.

Ectoparasite control with moxidectin encompasses economically significant external parasites affecting cattle production. Labeled indications include sucking lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus), biting lice (Bovicola bovis), and mange mites including sarcoptic mange (Sarcoptes scabiei var. bovis) and psoroptic mange (Psoroptes ovis). For lice control, moxidectin pour-on provides persistent activity that can protect against reinfestation for several weeks following treatment, reducing the likelihood of requiring retreatment during the winter months when lice burdens are typically highest. The horn fly (Haematobia irritans) control claim for the pour-on formulation provides additional value in fly management programs.

In sheep production, moxidectin is approved for control of multiple gastrointestinal nematode species with particular value against Haemonchus contortus, the highly pathogenic barber pole worm responsible for significant production losses and mortality in sheep worldwide. The extended duration of moxidectin activity is particularly valuable in sheep due to the rapid pasture recontamination that occurs with shorter-acting products. Persistent efficacy reduces the frequency of treatment required while maintaining protection against the most pathogenic parasites. Some evidence suggests moxidectin efficacy against certain ivermectin-resistant Haemonchus populations, supporting its role in resistance management strategies.

For horses, oral moxidectin gel formulations (Quest) are approved for control of large and small strongyles, ascarids, pinworms, hairworms, and bots. The extended persistent activity against small strongyle larval stages provides particular value, as these parasites have developed widespread resistance to many anthelmintics and represent a significant health challenge in managed horse populations. Quest Plus combines moxidectin with praziquantel for concurrent tapeworm control. The potent activity and extended duration of moxidectin have made it a key component of strategic, fecal egg count-based deworming programs in equine practice.

The standard dose of moxidectin for cattle by subcutaneous injection is 200 micrograms per kilogram of body weight (0.2 mg/kg). Using the 1% injectable formulation (10 mg/mL), this equates to 1 mL per 50 kg (110 pounds) of body weight. The injection is administered subcutaneously in the neck region, anterior to the shoulder, to minimize potential carcass effects from injection site reactions. Proper injection technique—using appropriately gauged needles (16-18 gauge), ensuring subcutaneous rather than intramuscular placement, limiting volume per injection site, and employing aseptic procedures—optimizes drug absorption and minimizes local tissue reactions.

For the cattle pour-on formulation, the dose is 500 micrograms per kilogram of body weight (0.5 mg/kg), applied topically along the midline of the back from the withers to the tailhead. Using the 0.5% pour-on solution (5 mg/mL), this corresponds to 1 mL per 10 kg (22 pounds) of body weight. Application should occur on dry cattle; wet hair coats can impair absorption and reduce efficacy. Animals should not be exposed to heavy rain or water sources immediately following pour-on application. The applicator equipment should be calibrated to deliver accurate volumes, as the extended duration of moxidectin activity amplifies the consequences of dosing errors.

Sheep receive moxidectin at 200 micrograms per kilogram (0.2 mg/kg) by oral drench using approved sheep formulations. Accurate weight determination is critical in sheep due to the variation in body size within flocks and the consequences of underdosing for both treatment efficacy and resistance selection. The use of scales or validated weight estimation methods is recommended. Oral administration should ensure the drench is deposited over the back of the tongue to minimize loss through spitting or regurgitation. Some markets have injectable formulations approved for sheep with specific dosing instructions that should be followed precisely.

For horses, oral moxidectin gel (Quest) is administered at 400 micrograms per kilogram (0.4 mg/kg). The oral syringe is calibrated by body weight, and the appropriate dose is dialed on the plunger ring before administration. The horse's mouth should be free of feed before administration, and the gel should be deposited on the back of the tongue. The syringe tip should be inserted through the interdental space and the gel delivered toward the base of the tongue to encourage swallowing. Following administration, briefly elevating the horse's head helps ensure the dose is swallowed rather than spit out.

Treatment timing should align with parasite epidemiology and the extended duration of activity that characterizes moxidectin. In cattle, pre-turnout treatment can provide extended protection during early grazing season when parasite challenge is developing. Fall treatment eliminates accumulated burdens before housing and can provide persistent protection through the early confinement period. For cattle grub control, treatment timing relative to grub migration (November-February in most of North America) is critical. The extended moxidectin activity can prevent new grub establishment for an extended period when treatment is administered after heel fly season.

Withdrawal times for moxidectin reflect its extended tissue persistence and must be strictly observed. Cattle treated with moxidectin injectable require 21 days before slaughter; pour-on treated cattle require 0 days for slaughter (no withdrawal) when applied at labeled dose. Sheep withdrawal times vary by formulation and market; label directions should be verified. Moxidectin cattle formulations are not approved for use in female dairy cattle of breeding age or in calves to be processed for veal. Extra-label use in dairy cattle is prohibited due to absence of established milk withdrawal times. Horses treated with Quest gel do not have withdrawal time requirements as horses are not typically food animals in the US market.

Moxidectin demonstrates an excellent safety profile in approved species when administered according to label directions, consistent with the favorable safety margins characteristic of macrocyclic lactone compounds. The selectivity of moxidectin for invertebrate glutamate-gated chloride channels provides protection against toxicity in mammalian hosts. Clinical trials and extensive field use have established that adverse effects are uncommon and generally mild when they occur at recommended doses. However, the enhanced lipophilicity and extended tissue persistence of moxidectin compared to some other macrocyclic lactones means that when adverse effects do occur, they may be more prolonged than with shorter-acting compounds.

Injection site reactions are the most commonly reported adverse effect following subcutaneous moxidectin administration in cattle. Transient swelling at the injection site may occur and can persist for several weeks. The reaction reflects tissue response to the drug formulation and is minimized through proper injection technique including appropriate needle selection, subcutaneous placement, and adherence to recommended volumes per site. In most cases, injection site reactions resolve without treatment and do not affect animal behavior or performance. In cattle destined for slaughter, awareness of potential injection site effects supports appropriate site selection in the neck region where any trim has minimal carcass impact.

Neurological signs including depression, ataxia, tremors, and hypersalivation have been reported following moxidectin administration, typically in association with overdose or administration to animals with increased susceptibility. The blood-brain barrier normally excludes macrocyclic lactones from the central nervous system, but barrier integrity may be compromised in very young animals, certain disease states, or specific genetic backgrounds. When neurological signs occur following moxidectin administration, the extended tissue persistence of the drug may result in prolonged duration of signs compared to shorter-acting macrocyclic lactones. Supportive care is indicated; there is no specific antidote. Most affected animals recover with appropriate supportive management, though recovery may take longer than with less lipophilic compounds.

In horses, moxidectin has a narrower safety margin compared to cattle, and adverse effects are more commonly reported in this species. Horses in poor body condition, debilitated, or heavily parasitized may experience adverse reactions including colic signs, diarrhea, or neurological disturbances following treatment. Young foals are particularly susceptible to toxicity due to incompletely developed blood-brain barriers. Quest gel is not recommended for use in foals under 6 months of age or horses in poor condition. Dose accuracy is critical in horses; overdosing can result in serious adverse effects. The calibrated dose syringe should be used according to instructions, and horse weight should be estimated carefully, erring toward underestimation if uncertain.

Host-parasite reactions can occur when treating heavily parasitized animals, particularly cattle with significant grub burdens treated during larval migration. The death of large numbers of Hypoderma larvae in sensitive tissues can cause inflammatory reactions. Grubs dying in the esophageal region may cause swelling resulting in bloat, while those dying near the spinal column may cause neurological signs including hindquarter weakness or paralysis. These reactions occur with any effective grub treatment and are not specific to moxidectin. Risk is minimized by treating during the recommended window (November-February in most of North America) when grubs have not reached critical anatomical locations.

Moxidectin cattle formulations are contraindicated for use in female dairy cattle of breeding age due to the absence of established milk withdrawal times. This restriction applies regardless of current lactation status—replacement dairy heifers and dry dairy cows are also excluded from approved use. The extended tissue persistence characteristic of moxidectin amplifies concerns about potential milk residues, as drug could continue to partition into milk for extended periods following treatment. Dairy producers requiring anthelmintic treatment in dairy breeding animals should select products with established milk withdrawal times, such as eprinomectin pour-on.

Moxidectin cattle products are not approved for use in calves intended for veal production. The restriction reflects the extended tissue residence of moxidectin combined with the relatively young slaughter age of veal calves. Veal producers requiring parasite control should select products specifically approved for their production system with withdrawal times compatible with the expected marketing timeline. When parasite treatment is necessary in animals destined for early slaughter, consultation with a veterinarian can identify appropriate product options.

In horses, moxidectin (Quest gel) is contraindicated in foals under 6 months of age due to increased susceptibility to toxicity in very young animals. The blood-brain barrier in young foals may be incompletely developed, allowing increased drug penetration into the central nervous system. The narrow safety margin of moxidectin in horses compared to cattle makes age restrictions particularly important. Additionally, moxidectin should not be used in horses that are debilitated, in poor body condition, underweight, or heavily parasitized, as these animals may experience severe adverse reactions. Horses should be assessed for body condition before treatment, and alternative anthelmintics with wider safety margins should be selected for compromised animals.

Animals with known hypersensitivity to macrocyclic lactone compounds should not receive moxidectin. While true allergic reactions are uncommon, animals that have demonstrated adverse reactions to moxidectin, ivermectin, doramectin, eprinomectin, or related compounds should be excluded from future macrocyclic lactone treatment. Cross-reactivity within the drug class has been documented. A thorough treatment history should be obtained, and anthelmintics from alternative chemical classes should be selected for animals with previous macrocyclic lactone adverse reactions. The extended duration of moxidectin's tissue presence means that any adverse reaction may be prolonged, making avoidance particularly important in sensitive individuals.

Concurrent administration of moxidectin with other macrocyclic lactone anthelmintics should be avoided to prevent cumulative toxicity from overlapping drug exposure. The extended tissue persistence of moxidectin means that significant drug concentrations may remain in tissues for weeks following administration, creating potential for interaction with subsequently administered macrocyclic lactones. This concern applies to combinations with ivermectin, doramectin, eprinomectin, or related compounds. When transitioning between macrocyclic lactone products or when animals are moved between properties with different deworming programs, adequate time should elapse to allow moxidectin clearance before administering alternative macrocyclic lactones.

Ionophore antibiotics interact with macrocyclic lactones through effects on P-glycoprotein transport mechanisms that normally limit drug penetration into the central nervous system. Ionophores including monensin, lasalocid, narasin, and related compounds are commonly used in cattle feeds for growth promotion and coccidiosis prevention. The potential for ionophores to interfere with P-glycoprotein function could theoretically increase moxidectin CNS penetration, elevating the risk of neurological adverse effects. While clinical problems from this interaction are uncommon at labeled doses of both drug classes, concurrent use warrants awareness and animal monitoring. The extended duration of moxidectin in tissues prolongs the window during which interaction could occur.

Other P-glycoprotein inhibitors beyond ionophores may affect moxidectin pharmacokinetics. Recognized P-glycoprotein inhibitors include ketoconazole, itraconazole, quinidine, verapamil, and cyclosporine. While specific interactions with moxidectin in livestock have not been extensively studied, theoretical concerns exist based on known pharmacology. When moxidectin treatment is planned for animals receiving concurrent medications, review of potential drug interactions and veterinary consultation is advisable. This is particularly relevant for valuable breeding stock or horses receiving multiple medications where drug interaction could have significant consequences.

In horses, concurrent administration of moxidectin with other anthelmintics requires consideration of the combined pharmacological burden. While Quest Plus combines moxidectin with praziquantel for concurrent roundworm and tapeworm control, this is a formulated combination with established safety. Ad hoc combination of moxidectin with other anthelmintic products should be approached cautiously, particularly with compounds that also have CNS effects. Vaccination timing relative to moxidectin administration has not been specifically studied, but general recommendations to separate anthelmintic treatment from vaccination by 48-72 hours when feasible may be prudent given moxidectin's extended duration of activity and potential immunomodulatory effects common to macrocyclic lactones.

Human safety precautions during moxidectin handling and administration minimize occupational exposure risk. The drug formulations, particularly pour-on products designed for transcutaneous absorption, can penetrate human skin if contact occurs. Waterproof gloves should be worn during all handling and application procedures. Direct skin contact should be avoided; if contact occurs, the affected area should be washed immediately with soap and water. Eye protection is recommended during use, as ocular exposure to formulation components can cause irritation. If accidental eye contact occurs, eyes should be flushed thoroughly with clean water and medical attention sought if irritation persists. Personnel with known sensitivity to macrocyclic lactone compounds should avoid handling moxidectin products.

Food safety considerations require strict attention to withdrawal times appropriate to the formulation and species. The zero-day meat withdrawal for cattle pour-on applies specifically to that formulation at labeled dose; the injectable formulation requires 21 days. These withdrawal times reflect formulation-specific pharmacokinetics and cannot be interchanged. Treated animals should be clearly identified and withdrawal dates documented to prevent inadvertent premature slaughter. Extra-label use in any species requires establishment of appropriate extended withdrawal times through resources such as the Food Animal Residue Avoidance Databank (FARAD) or veterinary consultation. Use in lactating dairy cattle is prohibited under all circumstances due to absence of established milk withdrawal.

Environmental stewardship considerations apply to moxidectin use given its potent toxicity to non-target invertebrates and extended environmental persistence. Residues excreted in feces of treated animals can affect dung beetle populations and other coprophagous invertebrates. The extended duration of moxidectin activity means feces may remain toxic to invertebrates for longer periods following treatment compared to shorter-acting products. Pour-on formulations pose environmental risk through potential run-off into water bodies; treatment should be avoided immediately before heavy rainfall, and recently treated cattle should not have direct access to streams or ponds. Strategic, evidence-based treatment approaches reduce environmental drug loading while maintaining effective parasite control.

Anthelmintic resistance to moxidectin has been documented in multiple parasite species despite its relatively recent introduction, driven by selection pressure from widespread use. While moxidectin may retain efficacy against some ivermectin-resistant parasite populations, continued exclusive use of moxidectin will eventually select for moxidectin resistance. Resistance management requires integrated approaches including accurate dosing, maintenance of refugia (untreated parasite populations), rotation among anthelmintic classes, and regular efficacy monitoring through fecal egg count reduction tests. When reduced moxidectin efficacy is suspected, consultation with a veterinarian or parasitologist is warranted to evaluate resistance status and adjust the parasite control program.

Proper product selection and use documentation support both efficacy and compliance objectives. The extended duration claims for moxidectin apply specifically to labeled indications and doses; extrapolating extended efficacy to extra-label uses is inappropriate without supporting data. Treatment records should document all relevant details including date, product, dose, animal identification, withdrawal dates, and administrator identity. These records enable traceback, demonstrate quality assurance compliance, and provide data for monitoring treatment outcomes. Understanding the specific attributes of moxidectin—including its extended activity, use restrictions, and potential for resistance—supports informed integration into comprehensive parasite management programs.

Moxidectin products should be stored according to manufacturer specifications to maintain product stability and efficacy. Injectable and pour-on cattle formulations should be stored at controlled room temperature, typically between 59°F and 86°F (15°C to 30°C), protected from direct sunlight and extreme temperature fluctuations. Horse oral gel formulations (Quest, Quest Plus) should also be stored at controlled room temperature according to label directions. Products should not be frozen, as this may affect product consistency and potency. Storage in climate-controlled areas rather than in vehicles or uninsulated buildings subject to temperature extremes helps maintain product integrity throughout the shelf life indicated on the package.

Multi-dose container handling for injectable formulations requires attention to aseptic technique to prevent contamination. The rubber stopper should be cleaned with alcohol or appropriate disinfectant before each needle entry. Needles should be changed frequently rather than reusing a single needle for multiple vial entries, which can introduce contaminants and dull the needle causing increased injection site trauma. Multi-dose vials should be used within the manufacturer-specified timeframe once opened; recording the opening date on containers supports appropriate use timelines. Pour-on formulations used with calibrated applicator equipment should have application systems maintained according to manufacturer instructions to ensure accurate dose delivery.

Disposal of moxidectin products and containers must comply with federal, state, and local environmental regulations. Moxidectin is highly toxic to aquatic organisms and beneficial invertebrates, and its extended environmental persistence amplifies concerns about improper disposal. Empty containers should be triple-rinsed before disposal, with rinsate applied to land areas away from water sources and drainage systems. Containers should be rendered non-reusable by puncturing or crushing. Used needles and syringes should be disposed of in designated sharps containers through appropriate medical waste channels. Unused or expired product should be disposed of through veterinary pharmaceutical return programs, agricultural chemical collection events, or hazardous waste facilities. Under no circumstances should product be disposed of by emptying into drains, water bodies, or areas where groundwater contamination could occur.

The dairy versus beef cattle distinction represents the primary production-type consideration for moxidectin use. Dairy breeds managed for milk production—including Holstein, Jersey, Brown Swiss, Guernsey, Ayrshire, and similar breeds—are subject to specific restrictions prohibiting moxidectin use in female cattle of breeding age due to absence of established milk withdrawal times. This restriction applies regardless of lactation status; replacement dairy heifers and dry dairy cows are also excluded. Dairy steers raised for beef production are not subject to dairy restrictions and may receive moxidectin according to beef cattle label directions with appropriate meat withdrawal observance.

Beef cattle across breeds may receive moxidectin according to label directions without breed-specific restrictions. The extended duration of moxidectin activity provides particular value in extensive grazing operations where cattle handling is infrequent. Body condition variation among breeds and individuals may influence the extended tissue persistence of this highly lipophilic compound; heavily conditioned cattle may demonstrate prolonged drug residence while lean cattle may clear the drug more rapidly. While labeled parameters accommodate the expected range of animal variation, awareness of these pharmacokinetic factors supports informed management of animals marketed near the end of withdrawal periods.

In sheep, moxidectin provides valuable extended-duration control of economically important parasites across all breeds. The extended efficacy is particularly advantageous in sheep production where frequent handling for treatment is challenging. Small-framed breeds and individuals in poor condition warrant careful attention to accurate dosing, as these animals have less margin for error. The efficacy of moxidectin against some ivermectin-resistant Haemonchus contortus populations has made it an important resistance management tool in sheep flocks, though exclusive reliance on any single compound will eventually drive resistance development.

Horse breed considerations center on the narrower safety margin of moxidectin in this species compared to ruminants. While no specific breed restrictions exist, certain populations warrant additional caution. Young horses under 6 months of age should not receive moxidectin regardless of breed. Horses of any breed that are debilitated, underweight, or heavily parasitized are at increased risk of adverse reactions and should receive alternative anthelmintics with wider safety margins. Miniature horses and ponies require accurate weight estimation to avoid overdosing, as the small body size means that even modest overestimation of weight delivers proportionally larger excess doses. Draft breeds and other large horses may approach the maximum dose per syringe, requiring attention to accurate dose delivery.

Within the macrocyclic lactone class, moxidectin is distinguished from avermectin compounds (ivermectin, doramectin, eprinomectin) by its milbemycin structure and extended pharmacokinetic profile. Ivermectin (Ivomec) remains the most widely used macrocyclic lactone and provides comparable spectrum with shorter duration of activity. Doramectin (Dectomax) offers an intermediate profile between ivermectin and moxidectin in terms of tissue persistence. Eprinomectin (Eprinex) provides the unique capability of treating lactating dairy cattle with zero milk withdrawal. Selection among macrocyclic lactones depends on target species and production class, duration of protection desired, resistance status of parasites on the operation, and specific management requirements including withdrawal time constraints.

Anthelmintics from different chemical classes provide essential alternatives for resistance management programs. Benzimidazoles including fenbendazole (Safe-Guard, Panacur) and albendazole (Valbazen) act through microtubule inhibition, offering a distinct mechanism from macrocyclic lactones. Levamisole (Prohibit, Levasole) represents the imidazothiazole class with nicotinic receptor agonist activity. These alternative classes can be used in rotation with macrocyclic lactones to diversify selection pressure and slow resistance development. When macrocyclic lactone resistance is confirmed or suspected based on fecal egg count reduction testing, alternative class products become primary treatment options while resistant populations may be managed through reduced reliance on the failing drug class.

Combination products incorporating moxidectin with other antiparasitic agents address broader parasite spectrum or concurrent infections. Quest Plus combines moxidectin with praziquantel for horses, providing concurrent activity against roundworms and tapeworms in a single treatment. Cattle combination products in some markets pair moxidectin with flukicides for concurrent control of nematodes and liver flukes. Combination with benzimidazoles provides complementary mechanisms that may help manage resistant parasite populations, though such combinations should be selected based on confirmed presence of target parasites and resistance testing rather than routine use. When selecting combination products, attention to the spectrum, withdrawal requirements for all active components, and evidence base for combined use ensures appropriate application in integrated parasite management programs.